A Frost & Sullivan White Paper
Faster Time to Market: Approaches to Biometrics for Emerging Biopharma Companies
Emerging Biopharma Companies (EBPs) are driving the growth of global clinical trials, creating a rising demand for advanced biometrics solutions to manage complex, data-intensive clinical development activities.
Download our Complimentary White Paper
Emerging Biopharma Companies (EBPs) are dominating the global clinical trial landscape, with clinical trial starts growing nearly 200% from 2011-2021. As EBPs often face resource constraints, they increasingly rely on CROs for clinical development, fueling significant growth in the CRO services market. The rise in trial complexity, use of real-world data, and stricter regulatory requirements are driving the need for advanced biometrics solutions to ensure high-quality, standardised data for successful regulatory submissions.
EBPs play an increasingly important role in biopharma R&D:
The volume and complexity of data from clinical trials are sharply increasing:
EBPs have a range of options for managing biometrics:
Key factors when choosing a CRO:
Download White Paper Now
"*" indicates required fields